Wells Fargo
SGMO

Wells Fargo’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Wells Fargo’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.46K Buy
38,330
+412
+1% +$164 ﹤0.01% 5984
2025
Q4 		$15.9K Sell
37,918
-1,989
-5% -$1.05K ﹤0.01% 5848
2025
Q3 		$26.9K Sell
39,907
-3,265
-8% -$1.76K ﹤0.01% 5722
2025
Q2 		$23.4K Sell
43,172
-9,758
-18% -$5.79K ﹤0.01% 5750
2025
Q1 		$34.7K Buy
52,930
+2,514
+5% +$2.66K ﹤0.01% 5509
2024
Q4 		$51.4K Sell
50,416
-9,650
-16% -$17.6K ﹤0.01% 5473
2024
Q3 		$52K Sell
60,066
-4,907
-8% -$3.6K ﹤0.01% 5329
2024
Q2 		$23.3K Sell
64,973
-69,384
-52% -$37.5K ﹤0.01% 5542
2024
Q1 		$90K Sell
134,357
-36,548
-21% -$26.5K ﹤0.01% 4950
2023
Q4 		$92.9K Sell
170,905
-153,766
-47% -$70.9K ﹤0.01% 4950
2023
Q3 		$195K Sell
324,671
-22,402
-6% -$24K ﹤0.01% 4370
2023
Q2 		$451K Sell
347,073
-167,305
-33% -$229K ﹤0.01% 4024
2023
Q1 		$905K Buy
514,378
+113,905
+28% +$325K ﹤0.01% 3447
2022
Q4 		$1.26M Sell
400,473
-45,526
-10% -$177K ﹤0.01% 3104
2022
Q3 		$2.19M Sell
445,999
-29,482
-6% -$151K ﹤0.01% 2661
2022
Q2 		$1.97M Sell
475,481
-108,601
-19% -$470K ﹤0.01% 2809
2022
Q1 		$3.39M Sell
584,082
-20,622
-3% -$123K ﹤0.01% 2798
2021
Q4 		$4.54M Sell
604,704
-52,110
-8% -$453K ﹤0.01% 2669
2021
Q3 		$5.92M Sell
656,814
-33,383
-5% -$330K ﹤0.01% 2683
2021
Q2 		$8.26M Buy
690,197
+31,242
+5% +$354K ﹤0.01% 2382
2021
Q1 		$8.26M Sell
658,955
-132,125
-17% -$1.78M ﹤0.01% 2356
2020
Q4 		$12.3M Sell
791,080
-57,940
-7% -$679K ﹤0.01% 1923
2020
Q3 		$8.02M Buy
849,020
+34,629
+4% +$375K ﹤0.01% 2068
2020
Q2 		$7.3M Buy
814,391
+145,254
+22% +$1.35M ﹤0.01% 2118
2020
Q1 		$4.26M Buy
669,137
+27,168
+4% +$202K ﹤0.01% 2365
2019
Q4 		$5.37M Sell
641,969
-196,161
-23% -$1.8M ﹤0.01% 2500
2019
Q3 		$7.58M Buy
838,130
+16,710
+2% +$187K ﹤0.01% 2170
2019
Q2 		$8.85M Buy
821,420
+164,784
+25% +$1.75M ﹤0.01% 2063
2019
Q1 		$6.26M Buy
656,636
+231
+0% +$2.36K ﹤0.01% 2335
2018
Q4 		$7.54M Sell
656,405
-233,829
-26% -$2.9M ﹤0.01% 2074
2018
Q3 		$15.1M Buy
890,234
+100,253
+13% +$1.52M ﹤0.01% 1737
2018
Q2 		$11.2M Buy
789,981
+234,346
+42% +$3.89M ﹤0.01% 1976
2018
Q1 		$10.6M Sell
555,635
-37,927
-6% -$811K ﹤0.01% 1963
2017
Q4 		$9.73M Buy
593,562
+118,794
+25% +$1.77M ﹤0.01% 2025
2017
Q3 		$7.12M Buy
474,768
+43,534
+10% +$481K ﹤0.01% 2244
2017
Q2 		$3.79M Buy
431,234
+135,464
+46% +$869K ﹤0.01% 2651
2017
Q1 		$1.54M Buy
295,770
+34,128
+13% +$137K ﹤0.01% 3416
2016
Q4 		$798K Sell
261,642
-30,994
-11% -$113K ﹤0.01% 3867
2016
Q3 		$1.35M Buy
292,636
+24,161
+9% +$123K ﹤0.01% 3265
2016
Q2 		$1.55M Buy
268,475
+5,360
+2% +$34.2K ﹤0.01% 3157
2016
Q1 		$1.59M Buy
263,115
+49,529
+23% +$297K ﹤0.01% 3088
2015
Q4 		$1.95M Buy
213,586
+44,875
+27% +$346K ﹤0.01% 2996
2015
Q3 		$952K Buy
168,711
+14,375
+9% +$119K ﹤0.01% 3538
2015
Q2 		$1.71M Buy
154,336
+46,975
+44% +$606K ﹤0.01% 3194
2015
Q1 		$1.68M Buy
107,361
+10,702
+11% +$166K ﹤0.01% 3158
2014
Q4 		$1.47M Buy
96,659
+4,470
+5% +$54.3K ﹤0.01% 3235
2014
Q3 		$994K Buy
92,189
+19,833
+27% +$259K ﹤0.01% 3477
2014
Q2 		$1.1M Buy
72,356
+27,661
+62% +$398K ﹤0.01% 3449
2014
Q1 		$809K Sell
44,695
-75,041
-63% -$1.45M ﹤0.01% 3626
2013
Q4 		$1.66M Buy
119,736
+37,441
+45% +$431K ﹤0.01% 3066
2013
Q3 		$863K Buy
82,295
+7,300
+10% +$72.5K ﹤0.01% 3443
2013
Q2 		$586K Buy
+74,995
New +$654K ﹤0.01% 3598

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Wells Fargo's SGMO Position: Q1 2026 in Review

Wells Fargo increased its SANGAMO THERAPEUTICS INC (SGMO) stake by 1.1% in Q1 2026, buying an estimated $164 and bringing the position to 38,330 shares worth $9.46K. The position accounts for ﹤0.01% of the portfolio, ranked #5984.

Wells Fargo first reported a position in SGMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $15.1M in Q3 2018. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Wells Fargo held 38,330 shares of SANGAMO THERAPEUTICS INC worth $9.46K as of Q1 2026.
  • Wells Fargo bought 412 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $164.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5984 holding.
  • Wells Fargo first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and has held it in 52 quarters since.
  • Wells Fargo's SANGAMO THERAPEUTICS INC position peaked at $15.1M in Q3 2018.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.